Centiva Capital LP Has $2.49 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Centiva Capital LP reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 43.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,509 shares of the medical research company's stock after selling 8,026 shares during the period. Centiva Capital LP's holdings in IQVIA were worth $2,490,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $27,000. Capital Performance Advisors LLP acquired a new stake in IQVIA during the 3rd quarter valued at $27,000. Park Place Capital Corp bought a new position in IQVIA during the third quarter worth $28,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter valued at $29,000. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on IQV. Redburn Atlantic started coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a "buy" rating and a $276.00 price target on the stock. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a research note on Monday, November 4th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Finally, Morgan Stanley cut their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $256.50.

IQVIA Trading Down 0.9 %

IQVIA stock traded down $1.88 during mid-day trading on Tuesday, hitting $199.91. 865,792 shares of the stock were exchanged, compared to its average volume of 1,176,075. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The firm's fifty day simple moving average is $217.89 and its two-hundred day simple moving average is $225.88. The stock has a market capitalization of $36.28 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 2.07 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.